Literature DB >> 15329911

Differential expression of Csk homologous kinase (CHK) in normal brain and brain tumors.

Sun-Ok Kim1, Shalom Avraham, Shuxian Jiang, Radoslaw Zagozdzon, Yigong Fu, Hava Karsenty Avraham.   

Abstract

BACKGROUND: Substantial evidence supports the suggestion that carboxyl-terminal Src kinase (Csk) and Csk homologous kinase (CHK), two negative regulatory kinases of the Src tyrosine kinase family, play distinct roles during development of the central nervous system (CNS).
METHODS: To further examine the individual roles of CHK and Csk in the CNS, the authors compared the expression patterns of Csk and CHK during differentiation of primary hippocampal neurons.
RESULTS: Opposite patterns of expression were observed for CHK and Csk. The authors observed an increase in CHK expression and a decline in Csk expression during differentiation of primary hippocampal neurons, but no difference in Src expression levels. CHK was also expressed in astrocytes and oligodendrocytes in a differentiation-dependent manner. However, CHK expression was not detected in brain endothelial cells, transformed neuroblastoma or astrocytoma cell lines, nor in primary human neuroblastoma and glioblastoma tumors (10 cases), indicating that loss of CHK expression is associated with human brain tumors. Treatment with antisense CHK oligodeoxynucleotides blocked the neuronal process formation of primary hippocampal neurons and neuronal differentiation of PC12 cells. CHK overexpression in primary hippocampal neurons using recombinant adenovirus infection resulted both in increased CHK kinase activity and changes in neuronal morphology. In addition, CHK overexpression in neuroblastoma and astrocytoma cells inhibited their growth and proliferation.
CONCLUSIONS: These findings strongly suggested that CHK may play a role in tumorigenesis and in the terminal differentiation of neurons within the CNS. Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15329911     DOI: 10.1002/cncr.20442

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Authors:  Julien Laffaire; Sibille Everhard; Ahmed Idbaih; Emmanuelle Crinière; Yannick Marie; Aurelien de Reyniès; Renaud Schiappa; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Joëlle Thillet; François Ducray
Journal:  Neuro Oncol       Date:  2010-10-05       Impact factor: 12.300

2.  Drosophila as a tool for personalized medicine: a primer.

Authors:  Yumi Kasai; Ross Cagan
Journal:  Per Med       Date:  2010-11       Impact factor: 2.512

3.  A novel risk model based on immune response predicts clinical outcomes and characterizes immunophenotypes in triple-negative breast cancer.

Authors:  Xunxi Lu; Zongchao Gou; Luoting Yu; Hong Bu
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

4.  Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine.

Authors:  Gahana Advani; Ya Chee Lim; Bruno Catimel; Daisy Sio Seng Lio; Nadia L Y Ng; Anderly C Chüeh; Mai Tran; Mohd Ishtiaq Anasir; Heather Verkade; Hong-Jian Zhu; Benjamin E Turk; Thomas E Smithgall; Ching-Seng Ang; Michael Griffin; Heung-Chin Cheng
Journal:  Cell Commun Signal       Date:  2017-08-07       Impact factor: 5.712

5.  Novel tumour suppressor roles for GZMA and RASGRP1 in Theileria annulata-transformed macrophages and human B lymphoma cells.

Authors:  Zineb Rchiad; Malak Haidar; Hifzur Rahman Ansari; Shahin Tajeri; Sara Mfarrej; Fathia Ben Rached; Abhinav Kaushik; Gordon Langsley; Arnab Pain
Journal:  Cell Microbiol       Date:  2020-09-29       Impact factor: 3.715

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.